Bazex-Dupre-Christol Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Bazex-Dupre-Christol Syndrome (BDC) is characterized clinically by multiple basal cell carcinomas of the face that primarily occur in the second and third decade of life, follicular atrophoderma primarily of the dorsum sides of the hands and feet, and generalized hypotrichosis, occasionally with pili torti and trichorrhexis nodosa. Milia, hypohidrosis, and calcifying epithelial tumors are all symptoms of BDC. Four members of one family with BDC syndrome, a mother and her three daughters, were reported in this study. The major clinical features of BDC were very typical in the mother and one of the daughters, whereas the other two daughters only had follicular atrophoderma, milia, and hypotrichosis. Bazex-Dupre-Christol Syndrome is a hereditary multiple basal cell carcinoma (BCC) syndromes whose inheritance pattern is X-linked dominant, implying that all daughters of affected mothers should have this disease.
• Bazex-Dupre-Christol Syndrome incidence ranges from 1 to 1.5 cases per million population.

Thelansis’s “Bazex-Dupre-Christol Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033\” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bazex-Dupre-Christol Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Bazex-Dupre-Christol Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Bazex-Dupre-Christol Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Bazex-Dupre-Christol Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033